Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/38193

Target Organs and Levels of Evidence for GMM-14

Toxicology and Carcinogenesis Studies of 3'-Azido-3'-Deoxythymidine (AZT) (CASRN 30516-87-1) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (in Utero and Postnatal Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
3'-Azido-3'-deoxythymidine (AIDS)
30516-87-1
02/00/2012 Pyrimidine nucleoside analog with antiviral activity used in the treatment of AIDS (Merck 1989) Gavage
30-Week Study: 0 or 240 mg/kg (GD 12-18 -- AZT only); 0 or 120 mg/kg (PND 1-10); 0 or 240 mg/kg (PND 11-9 mo) -- 45-Week Study: 0, 80, 160, or 240 mg/kg (GD 12-18 -- AZT only); 0, 40, 80, or 120 mg/kg (PND 1-10); 0, 80, 160, or 240 mg/kg (PND 11-9 mo) -- 45-Week Stop-Study: 0 or 240 mg/kg (GD 12-18 -- AZT only); 0 or 40 mg/kg (PND 1-8); pups were then maintained on study until 45 weeks of age without dosing
National Center for Toxicological Research

Levels of evidence information for the in Utero/Postnatal Gavage Studies of AZT in C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice
  Male C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice Female C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice
  30 Week Study 45 Week Study 45 Week Stop-Study 30 Week Study 45 Week Study 45 Week Stop-Study
Levels of Evidence Clear evidence Clear evidence Clear evidence Equivocal evidence Equivocal evidence Equivocal evidence
May Have Been Related
  • Malignant Lymphoma: 0/27, 3/26 (30-Week Study)
None None None
  • Malignant lymphoma: 0/26, 0/27, 1/27, 3/27 (45-Week Study)
None
Neoplastic Lesions None
  • Liver: hepatocellular adenoma 3/26, 2/27, 6/27, 9/27 (45-Week Study)
  • Liver: hepatocelluar adenoma 3/24, 5/25; hepatocellular adenoma or carcinoma 3/24, 7/25 (45-Week Stop-Study)
None None None
Non-Neoplastic Lesions None None None None None None